108 related articles for article (PubMed ID: 20836522)
1. (-)-CHANA, a fluorogenic probe for detecting amyloid binding alcohol dehydrogenase HSD10 activity in living cells.
Muirhead KE; Froemming M; Li X; Musilek K; Conway SJ; Sames D; Gunn-Moore FJ
ACS Chem Biol; 2010 Dec; 5(12):1105-14. PubMed ID: 20836522
[TBL] [Abstract][Full Text] [Related]
2. Harnessing functional plasticity of enzymes: a fluorogenic probe for imaging 17beta-HSD10 dehydrogenase, an enzyme involved in Alzheimer's and Parkinson's diseases.
Froemming MK; Sames D
J Am Chem Soc; 2007 Nov; 129(46):14518-22. PubMed ID: 17958419
[TBL] [Abstract][Full Text] [Related]
3. Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders.
Yang SY; He XY; Isaacs C; Dobkin C; Miller D; Philipp M
J Steroid Biochem Mol Biol; 2014 Sep; 143():460-72. PubMed ID: 25007702
[TBL] [Abstract][Full Text] [Related]
4. Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase.
Yang SY; He XY; Schulz H
Trends Endocrinol Metab; 2005; 16(4):167-75. PubMed ID: 15860413
[TBL] [Abstract][Full Text] [Related]
5. Morphology-Specific Inhibition of β-Amyloid Aggregates by 17β-Hydroxysteroid Dehydrogenase Type 10.
Aitken L; Quinn SD; Perez-Gonzalez C; Samuel ID; Penedo JC; Gunn-Moore FJ
Chembiochem; 2016 Jun; 17(11):1029-37. PubMed ID: 26991863
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics.
Kissinger CR; Rejto PA; Pelletier LA; Thomson JA; Showalter RE; Abreo MA; Agree CS; Margosiak S; Meng JJ; Aust RM; Vanderpool D; Li B; Tempczyk-Russell A; Villafranca JE
J Mol Biol; 2004 Sep; 342(3):943-52. PubMed ID: 15342248
[TBL] [Abstract][Full Text] [Related]
7. Novel Benzothiazole-based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer's Disease Treatment.
Aitken L; Benek O; McKelvie BE; Hughes RE; Hroch L; Schmidt M; Major LL; Vinklarova L; Kuca K; Smith TK; Musilek K; Gunn-Moore FJ
Molecules; 2019 Jul; 24(15):. PubMed ID: 31362457
[No Abstract] [Full Text] [Related]
8. Interactions of 17β-Hydroxysteroid Dehydrogenase Type 10 and Cyclophilin D in Alzheimer's Disease.
Kristofikova Z; Springer T; Gedeonova E; Hofmannova A; Ricny J; Hromadkova L; Vyhnalek M; Laczo J; Nikolai T; Hort J; Petrasek T; Stuchlik A; Vales K; Klaschka J; Homola J
Neurochem Res; 2020 Apr; 45(4):915-927. PubMed ID: 31997103
[TBL] [Abstract][Full Text] [Related]
9. Hydroxysteroid (17β) dehydrogenase X in human health and disease.
Yang SY; He XY; Miller D
Mol Cell Endocrinol; 2011 Aug; 343(1-2):1-6. PubMed ID: 21708223
[TBL] [Abstract][Full Text] [Related]
10. Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10.
Boutin S; Roy J; Maltais R; Alata W; Calon F; Poirier D
Bioorg Med Chem Lett; 2018 Dec; 28(22):3554-3559. PubMed ID: 30297283
[TBL] [Abstract][Full Text] [Related]
11. A two-photon fluorescent probe for amyloid-β plaques in living mice.
Heo CH; Kim KH; Kim HJ; Baik SH; Song H; Kim YS; Lee J; Mook-jung I; Kim HM
Chem Commun (Camb); 2013 Feb; 49(13):1303-5. PubMed ID: 23295364
[TBL] [Abstract][Full Text] [Related]
12. Intracellular oxidation of allopregnanolone by human brain type 10 17beta-hydroxysteroid dehydrogenase.
He XY; Wegiel J; Yang SY
Brain Res; 2005 Apr; 1040(1-2):29-35. PubMed ID: 15804423
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Type 10 17β-Hydroxysteroid Dehydrogenase in the Pathogenesis of Infantile Neurodegeneration and Alzheimer's Disease.
He XY; Frackowiak J; Dobkin C; Brown WT; Yang SY
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139430
[TBL] [Abstract][Full Text] [Related]
14. In vitro study of interaction of 17β-hydroxysteroid dehydrogenase type 10 and cyclophilin D and its potential implications for Alzheimer's disease.
Hemmerová E; Špringer T; Krištofiková Z; Homola J
Sci Rep; 2019 Nov; 9(1):16700. PubMed ID: 31723183
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Hroch L; Benek O; Guest P; Aitken L; Soukup O; Janockova J; Musil K; Dohnal V; Dolezal R; Kuca K; Smith TK; Gunn-Moore F; Musilek K
Bioorg Med Chem Lett; 2016 Aug; 26(15):3675-8. PubMed ID: 27287370
[TBL] [Abstract][Full Text] [Related]
16. Physiologically relevant fluorescent assay for identification of 17β-hydroxysteroid dehydrogenase type 10 inhibitors.
Schmidt M; Vaskova M; Rotterova A; Fiandova P; Miskerikova M; Zemanova L; Benek O; Musilek K
J Neurochem; 2023 Oct; 167(2):154-167. PubMed ID: 37458164
[TBL] [Abstract][Full Text] [Related]
17. Undetectable levels of CSF amyloid-β peptide in a patient with 17β-hydroxysteroid dehydrogenase deficiency.
Ortez C; Villar C; Fons C; Duarte ST; Pérez A; García-Villoria J; Ribes A; Ormazábal A; Casado M; Campistol J; Vilaseca MA; García-Cazorla A
J Alzheimers Dis; 2011; 27(2):253-7. PubMed ID: 21841256
[TBL] [Abstract][Full Text] [Related]
18. Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation.
Benek O; Vaskova M; Miskerikova M; Schmidt M; Andrys R; Rotterova A; Skarka A; Hatlapatkova J; Karasova JZ; Medvecky M; Hroch L; Vinklarova L; Fisar Z; Hroudova J; Handl J; Capek J; Rousar T; Kobrlova T; Dolezal R; Soukup O; Aitken L; Gunn-Moore F; Musilek K
Eur J Med Chem; 2023 Oct; 258():115593. PubMed ID: 37390508
[TBL] [Abstract][Full Text] [Related]
19. Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis.
Kristofikova Z; Ricny J; Kaping D; Klaschka J; Kotoucova J; Bartos A
Biomark Med; 2018 Dec; 12(12):1331-1340. PubMed ID: 30520659
[TBL] [Abstract][Full Text] [Related]
20. Study of Biomolecular Interactions of Mitochondrial Proteins Related to Alzheimer's Disease: Toward Multi-Interaction Biomolecular Processes.
Hemmerová E; Špringer T; Krištofiková Z; Homola J
Biomolecules; 2020 Aug; 10(9):. PubMed ID: 32825572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
